About this Research Topic
Non-alcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated fatty liver disease (MAFLD) which is suggested as a more appropriate overarching term, is the commonest liver disease affecting up to 20%~35% of the population across countries. A subset of patients with NAFLD will go on to develop non-alcoholic steatohepatitis (NASH), which is a leading cause of hepatocellular carcinoma and is also expected to become the most frequent indication for liver transplantation within a decade. Due to the increasing prevalence and liver-related morbidity and mortality, NAFLD/MAFLD has become a huge public health problem worldwide.
The immense disease burden prompts extensive research on the development of pharmacological interventions for it. Although currently no approved pharmacological options for NAFLD/MAFLD, exciting results are emerging from various preclinical studies and ongoing clinical trials. The substantial advances in novel targets, target-directed synthetic compounds, natural products, gut microbiota regulators and nutrients, could open new avenues for NAFLD/MAFLD treatment.
This Research Topic aims at highlighting the most recent scientific contributions in the research on the therapeutic approaches for NAFLD/MAFLD, ranging from preclinical research to clinical translational studies. The therapeutic approaches could be the discovery of novel targets, novel active synthetic and natural compounds, the repurposing of available drugs, and the supplement of nutraceuticals, etc. These efforts will provide new lead compounds for drug development and contribute to the options of NAFLD/MAFLD therapy.
We welcome original research, reviews, systematic reviews, meta-analysis, short communications, and clinical trials. Potential topics include but are not limited to:
● Novel therapeutic targets for NAFLD/MAFLD
● Synthesis and evaluation of novel active compounds for the treatment of NAFLD/MAFLD
● Pre-clinical and clinical studies of herbal medicines in the treatment of NAFLD/MAFLD
● Repurposing of current drugs with benefit to NAFLD/MAFLD
● Benefit of gut microbiota regulators and nutrients to NAFLD/MAFLD
The immense disease burden prompts extensive research on the development of pharmacological interventions for it. Although currently no approved pharmacological options for NAFLD/MAFLD, exciting results are emerging from various preclinical studies and ongoing clinical trials. The substantial advances in novel targets, target-directed synthetic compounds, natural products, gut microbiota regulators and nutrients, could open new avenues for NAFLD/MAFLD treatment.
This Research Topic aims at highlighting the most recent scientific contributions in the research on the therapeutic approaches for NAFLD/MAFLD, ranging from preclinical research to clinical translational studies. The therapeutic approaches could be the discovery of novel targets, novel active synthetic and natural compounds, the repurposing of available drugs, and the supplement of nutraceuticals, etc. These efforts will provide new lead compounds for drug development and contribute to the options of NAFLD/MAFLD therapy.
We welcome original research, reviews, systematic reviews, meta-analysis, short communications, and clinical trials. Potential topics include but are not limited to:
● Novel therapeutic targets for NAFLD/MAFLD
● Synthesis and evaluation of novel active compounds for the treatment of NAFLD/MAFLD
● Pre-clinical and clinical studies of herbal medicines in the treatment of NAFLD/MAFLD
● Repurposing of current drugs with benefit to NAFLD/MAFLD
● Benefit of gut microbiota regulators and nutrients to NAFLD/MAFLD
Keywords: non-alcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, therapy, management, non-alcoholic fatty liver disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
